Synairgen, a company developing novel therapies for asthma and COPD, has selected Alpha Biologics to help with the advancement of its growth factor drug development program. Alpha will develop a scaleable manufacturing process for Synairgen’s optimized growth factor to support preclinical and clinical development. Richard Marsden, Synairgen’s managing director, said, “We have significant confidence in our growth factor drug development program for asthma to restore barrier func...